Sub menu

 

 

ACV meeting statement, meeting 50, 4 December 2024

Advisory Committee on Vaccines
Published

Section A: Premarket registration applications

At this meeting the committee provided advice on one application under evaluation by the TGA.

Active ingredient (TRADENAME)SponsorTherapeutic areaApplication designations
Application for a 'new vaccine' containing a new active substance (new chemical entity or new biological entity) not currently approved in Australia (Application Type A)

pneumococcal purified capsular polysaccharides

(Tradename to be confirmed)

Merck Sharp & Dohme (Australia) Pty LtdActive immunisation for the prevention of pneumococcal disease in adults 

The date of commencement of the evaluation of the application is available at Prescription medicines: Applications under evaluation.

Further details of the ACV discussion and advice associated with items may be released within the Australian Public Assessment Reports (AusPAR).

Section B: Post-market items

The ACV was not asked to provide advice on a post-market or safety issue.

Further information

For further information on the Advisory Committee on Vaccines, please visit: Advisory Committee on Vaccines (ACV) or contact the ACV Secretary by email: ACV@health.gov.au.

Outcome of